The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study

Research paper by Mary R. Lee, Jenica D. Tapocik, Mwlod Ghareeb, Melanie L. Schwandt, Alexandra A. Dias, April N. Le, Enoch Cobbina, Lisa A. Farinelli, Sofia Bouhlal, Mehdi Farokhnia, Markus Heilig, Fatemeh Akhlaghi, Lorenzo Leggio

Indexed on: 08 May '18Published on: 04 May '18Published in: Molecular Psychiatry

---

Join Sparrho today to stay on top of science

Discover, organise and share research that matters to you

Join for free

Join Sparrho today to stay on top of science

Discover, organise and share research that matters to you

Join for free

---

---

Abstract

Authors: Mary R. Lee, Jenica D. Tapocik, Mwlod Ghareeb, Melanie L. Schwandt, Alexandra A. Dias, April N. Le, Enoch Cobbina, Lisa A. Farinelli, Sofia Bouhlal, Mehdi Farokhnia, Markus Heilig, Fatemeh Akhlaghi, Lorenzo Leggio Article URL: http://feeds.nature.com/~r/mp/rss/current/~3/_EH_lTFVBMY/s41380-018-0064-y Citation: The novel ghrelin receptor inverse agonist PF-5190457 administered with alcohol: preclinical safety experiments and a phase 1b human laboratory study, Published online: 2018-05-04; doi:10.1038/s41380-018-0064-y Publication Date: 2018-05-04 Journal: Molecular Psychiatry